No connection

Search Results

IMTX vs PGEN

IMTX
Immatics N.V.
BEARISH
Price
$10.43
Market Cap
$1.4B
Sector
Healthcare
AI Confidence
85%
PGEN
Precigen, Inc.
BEARISH
Price
$3.95
Market Cap
$1.4B
Sector
Healthcare
AI Confidence
90%

Valuation

P/E Ratio
IMTX
--
PGEN
--
Forward P/E
IMTX
-5.91
PGEN
-17.95
P/B Ratio
IMTX
2.5
PGEN
66.95
P/S Ratio
IMTX
28.98
PGEN
144.36
EV/EBITDA
IMTX
-5.47
PGEN
-13.53

Profitability

Gross Margin
IMTX
-280.87%
PGEN
0.0%
Operating Margin
IMTX
-196.76%
PGEN
-474.61%
Profit Margin
IMTX
0.0%
PGEN
0.0%
ROE
IMTX
-37.1%
PGEN
-571.97%
ROA
IMTX
-18.08%
PGEN
-44.3%

Growth

Revenue Growth
IMTX
-64.9%
PGEN
283.6%
Earnings Growth
IMTX
--
PGEN
--

Financial Health

Debt/Equity
IMTX
0.03
PGEN
4.7
Current Ratio
IMTX
11.72
PGEN
3.09
Quick Ratio
IMTX
11.07
PGEN
2.74

Dividends

Dividend Yield
IMTX
--
PGEN
--
Payout Ratio
IMTX
0.0%
PGEN
0.0%

AI Verdict

IMTX BEARISH

IMTX exhibits severe fundamental distress, highlighted by a Piotroski F-Score of 1/9, indicating critical weakness in financial health and operational efficiency. While the company maintains an exceptionally strong liquidity position (Current Ratio of 11.72) and low debt, these are overshadowed by a catastrophic 64.90% year-over-year decline in revenue and deeply negative gross margins (-280.87%). The stock currently trades at a speculative premium with a Price/Sales ratio of 28.98 despite shrinking top-line growth. Any potential upside is driven by analyst price targets ($18.75) rather than current financial performance.

Strengths
Exceptional short-term liquidity with a Current Ratio of 11.72
Very low leverage with a Debt/Equity ratio of 0.03
Significant analyst price target upside (Target: $18.75 vs Price: $10.43)
Risks
Severe revenue contraction (-64.90% YoY)
Extreme operational inefficiency with Gross Margins at -280.87%
Critical Piotroski F-Score (1/9) signaling fundamental decay
PGEN BEARISH

PGEN exhibits critical financial instability, highlighted by a Piotroski F-Score of 1/9, indicating severe fundamental weakness. While the company shows hyper-growth in revenue (283.60% YoY), this is decoupled from profitability, as evidenced by a catastrophic ROE of -571.97% and an operating margin of -474.61%. Valuation metrics are extreme, with a Price/Book ratio of 66.95 and Price/Sales of 144.36, suggesting the stock is trading on pure speculation rather than intrinsic value. The bearish insider sentiment, characterized by a $15.75M sale, further undermines the bullish analyst price targets.

Strengths
Exceptional YoY revenue growth of 283.60%
Strong short-term liquidity with a Current Ratio of 3.09
Significant 1-year price appreciation (+188.3%)
Risks
Extreme fundamental weakness (Piotroski F-Score 1/9)
Severe overvaluation relative to assets (P/B 66.95) and sales (P/S 144.36)
High leverage with a Debt/Equity ratio of 4.70

Compare Another Pair

IMTX vs PGEN: Head-to-Head Comparison

This page compares Immatics N.V. (IMTX) and Precigen, Inc. (PGEN) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile